doi:10.3109/0284186X.2014.974829BinayKumarShahKrishnaBilasGhimireEBSCO_AspActa OncologicaShah BK, Ghimire KB. Survival in adult stage I follicular lym- phoma treated with and without radiotherapy - a population- based study. Acta Oncol. 2015; 54 : 951-953....
Follicular lymphomais the second most common lymphoma in North America and Western Europe and is a neoplasm of follicle center B-cells consisting of a mixture of centrocytes and centroblasts. The pattern of lymph node involvement is at least partially follicular. Other terminologies used for this ...
Nodal status of malignant lymphoma in pelvic and retroperitoneal lymphatic pathways: Comparison of integrated PET/CT with or without contrast enhancement Aim To determine the diagnostic accuracy of integrated contrast-enhanced positron emission tomography (PET) and computed tomography (CT), as compared wit...
Content on this site has been developed by Robert G. Miller, a “retired” college dean and a follicular lymphoma survivor diagnosed over 36 years ago, currently in excellent health, no longer with evidence of lymphoma, confirmed by scan. I started the LymphomaSurvival website with commencement ...
Even though in rituximab era, HT is still a serious event affecting the prognosis and survival of follicular lymphoma, especially in patients with subsequent transformation, with a 5-year PFS rate of less than 20% and 5-year OS rate of less than 70% [3]. The transformation of follicular ...
Follicular lymphoma (FL) is a low-grade B-cell malignancy that transforms into a highly aggressive and lethal disease at a rate of 2% per year. Perfect isolation of the malignant B-cell population from a surgical biopsy is a significant challenge, masking important FL biology, such as immune...
Using Surveillance, Epidemiology and End Results (SEER)-Medicare data (19962010), we compared survival and toxicity outcomes in 6993 patients older than 65 years with follicular (FL), nodal marginal zone (NMZL) and small lymphocytic lymphoma (SLL) receiving front-line therapy with rituximab (R),...
Conclusion The combination of 25mg of lenalidomide for 14 days with 21-day R-CHOP cycles is well tolerated and yields a high rate of complete remission in patients with high tumor burden follicular lymphoma. Disclosures: Tilly: Roche: Honoraria; Celgene: Honoraria, Membership on an entity's ...
address this issue. A second question is whether the BCR directly promotes B-cell survival, or whether life-saving signals in B cells are ultimately provided by alternative receptors whose expression are promoted by the BCR. In this regard, the BCR upregulates expression of BR3, one of the ...
We assessed stage-specific trends in primary therapy and relative survival among adult follicular lymphoma (FL) patients diagnosed in the Netherlands between 1989–2016 (N = 12,372; median age, 62 years; and 21% stage I disease). Patients were stratified by disease stage and subsequently ...